Back to Search
Start Over
Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature
- Source :
- Seminars in arthritis and rheumatism. 37(5)
- Publication Year :
- 2007
-
Abstract
- Objective To analyze the clinical efficacy of anti-tumor necrosis factor (TNF)-α therapy in the SAPHO (synovitis, acne, pustulosis, hyperostosis, osteitis) syndrome. We describe 2 new cases with ilium osteitis as the main SAPHO syndrome feature and review reported cases treated with anti-TNF-α. Methods A literature search of SAPHO syndrome cases treated with TNF-α blocking therapy with special emphasis on osteoarticular and skin responses was performed. Results Eighteen cases were identified: 17 SAPHO syndrome and 1 chronic recurrent multifocal osteomyelitis, a juvenile variant of SAPHO syndrome. Sixteen were reported cases and 2 were nonreported cases seen in our arthritis unit. Sixteen patients received infliximab and 2 received etanercept, with an early, sustained clinical improvement in most cases. Conclusions Anti-TNF-α therapies are effective treatment for patients with refractory SAPHO syndrome, not only for cutaneous lesions but also for persistent bone lesions such as osteitis.
- Subjects :
- SAPHO syndrome
medicine.medical_specialty
Hyperostosis
Anti-Inflammatory Agents
Etanercept
Diagnosis, Differential
Ilium
Rheumatology
Synovitis
medicine
Humans
Osteitis
business.industry
Tumor Necrosis Factor-alpha
Chronic recurrent multifocal osteomyelitis
Acquired Hyperostosis Syndrome
Antibodies, Monoclonal
medicine.disease
Pustulosis
Infliximab
Surgery
Anesthesiology and Pain Medicine
Treatment Outcome
medicine.symptom
business
medicine.drug
Subjects
Details
- ISSN :
- 00490172
- Volume :
- 37
- Issue :
- 5
- Database :
- OpenAIRE
- Journal :
- Seminars in arthritis and rheumatism
- Accession number :
- edsair.doi.dedup.....05dd711bd46bef14cf2f5d72302c9566